Skip to main content
Erschienen in: Archives of Gynecology and Obstetrics 4/2024

11.09.2023 | Gynecologic Oncology

Novel predictors for identifying cervical minimal deviation adenocarcinoma patients with poor prognosis: a long-term observational study in a tertiary centre

verfasst von: Yiting Bao, Hao Zhang, Wu Huang, Xukai Luo, Liangqing Yao, Guannan Feng, Lei Yuan

Erschienen in: Archives of Gynecology and Obstetrics | Ausgabe 4/2024

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To elucidate the clinicopathological features and prognostic factors of minimal deviation adenocarcinoma (MDA) of the uterine cervix, a clinically rare but highly invasive disease.

Methods

This was a retrospective, observational, real-world study of 43 patients with pathologically confirmed MDA at the Obstetrics and Gynaecology Hospital of Fudan University between November 2010 and November 2021. Baseline clinicopathological data were collected and reviewed. Prognostic factors for progression-free survival (PFS) and overall survival (OS) were investigated by univariate and multivariate Cox proportional hazards analyses.

Results

Chief complaints included irregular vaginal discharge and/or bleeding (74.4%). Preoperative diagnosis was difficult, the detection rate was low (36.8%), all cases showed endophytic lesions, and 88.4% had deep stromal invasion, with biologically aggressive characteristics. The ovarian metastasis rate was high (16.3%, 7/43). The median maximum diameter of the tumour (MDOT) was 4.3 cm (range, 0.5–8.0 cm). MDOT was significantly associated with OS (P = 0.009), and the optimal cut-off value to define bulky MDA was 5.5 cm (P < 0.0001, χ= 21.161) using X-tile software. Independent prognostic factors included MDOT (HR = 10.095, P = 0.001) and ovarian metastasis (HR = 5.888, P = 0.008) for OS and MDOT (HR = 3.944, P = 0.028), ovarian metastasis (HR = 9.285, P = 0.001), and deep infiltration (HR = 3.627, P = 0.048) for PFS.

Conclusion

Endophytic lesion development and ovarian metastasis are likely in MDA. A bulky tumour and ovarian metastasis indicate a worse prognosis. Given the special biological features of MDA, it is more appropriate to use 5.5 cm as the threshold for defining a bulky tumour than it is to use 4 cm. Ovary removal should be given higher priority to improve prognosis.
Literatur
1.
Zurück zum Zitat Li G, Jiang W, Gui S, Xu C (2010) Minimal deviation adenocarcinoma of the uterine cervix. Int J Gynaecol Obstet 110(2):89–92CrossRefPubMed Li G, Jiang W, Gui S, Xu C (2010) Minimal deviation adenocarcinoma of the uterine cervix. Int J Gynaecol Obstet 110(2):89–92CrossRefPubMed
2.
Zurück zum Zitat Wells M (2003) WHO classification of tumors pathology and genetic tumors of the breast and female genital organs, vol 15. IARC Press, Lyon, pp 262–276 Wells M (2003) WHO classification of tumors pathology and genetic tumors of the breast and female genital organs, vol 15. IARC Press, Lyon, pp 262–276
3.
Zurück zum Zitat Loureiro J, Oliva E (2014) The spectrum of cervical glandular neoplasia and issues in differential diagnosis. Arch Pathol Lab Med 138(4):453–483CrossRefPubMed Loureiro J, Oliva E (2014) The spectrum of cervical glandular neoplasia and issues in differential diagnosis. Arch Pathol Lab Med 138(4):453–483CrossRefPubMed
4.
Zurück zum Zitat Naucler P, Ryd W, Törnberg S, Strand A, Wadell G, Elfgren K et al (2007) Human papillomavirus and Papanicolaou tests to screen for cervical cancer. N Engl J Med 357(16):1589–1597CrossRefPubMed Naucler P, Ryd W, Törnberg S, Strand A, Wadell G, Elfgren K et al (2007) Human papillomavirus and Papanicolaou tests to screen for cervical cancer. N Engl J Med 357(16):1589–1597CrossRefPubMed
5.
Zurück zum Zitat Kurman RJ, Carcangiu ML, Herrington CS (eds) (2014) WHO classification of tumors of female reproductive organs, IARC Press, Lyon, 4th ed. 184-186 Kurman RJ, Carcangiu ML, Herrington CS (eds) (2014) WHO classification of tumors of female reproductive organs, IARC Press, Lyon, 4th ed. 184-186
6.
Zurück zum Zitat Höhn AK, Brambs CE, Hiller GGR, May D, Schmoeckel E, Horn LC (2021) 2020 WHO classification of female genital tumors. Geburtshilfe Frauenheilkd 81(10):1145–1153CrossRefPubMedPubMedCentral Höhn AK, Brambs CE, Hiller GGR, May D, Schmoeckel E, Horn LC (2021) 2020 WHO classification of female genital tumors. Geburtshilfe Frauenheilkd 81(10):1145–1153CrossRefPubMedPubMedCentral
7.
Zurück zum Zitat Mikami Y (2020) Gastric-type mucinous carcinoma of the cervix and its precursors-historical overview. Histopathology 76(1):102–111CrossRefPubMed Mikami Y (2020) Gastric-type mucinous carcinoma of the cervix and its precursors-historical overview. Histopathology 76(1):102–111CrossRefPubMed
8.
Zurück zum Zitat Zhu L, Yi X, Lin B, Gao A, Zhao W, Zhang Y et al (2013) A clinicopathological and immunohistochemical study of minimal deviation adenocarcinoma of the uterine cervix. Med Hypotheses 80(5):643–648CrossRefPubMed Zhu L, Yi X, Lin B, Gao A, Zhao W, Zhang Y et al (2013) A clinicopathological and immunohistochemical study of minimal deviation adenocarcinoma of the uterine cervix. Med Hypotheses 80(5):643–648CrossRefPubMed
9.
Zurück zum Zitat Lee MH, Kim ES, Choi MC, Heo JH, Jang JH, Jung SG et al (2018) Minimal deviation adenocarcinoma (adenoma malignum) of the uterine cervix: clinicopathological analysis of 17 cases. Obstet Gynecol Sci 61(5):590–597CrossRefPubMedPubMedCentral Lee MH, Kim ES, Choi MC, Heo JH, Jang JH, Jung SG et al (2018) Minimal deviation adenocarcinoma (adenoma malignum) of the uterine cervix: clinicopathological analysis of 17 cases. Obstet Gynecol Sci 61(5):590–597CrossRefPubMedPubMedCentral
10.
Zurück zum Zitat Heinritz W, Strenge S, Kujat A, Hockel M, Froster UG (2008) Different phenotypes including gynecological cancer in three female patients with Peutz–Jeghers syndrome and mutations in the STK11 gene. Onkologie 31(11):625–628PubMed Heinritz W, Strenge S, Kujat A, Hockel M, Froster UG (2008) Different phenotypes including gynecological cancer in three female patients with Peutz–Jeghers syndrome and mutations in the STK11 gene. Onkologie 31(11):625–628PubMed
11.
Zurück zum Zitat Kuragaki C, Enomoto T, Ueno Y, Sun H, Fujita M, Nakashima R et al (2003) Mutations in the STK11 gene characterize minimal deviation adenocarcinoma of the uterine cervix. Lab Invest 83(1):35–45CrossRefPubMed Kuragaki C, Enomoto T, Ueno Y, Sun H, Fujita M, Nakashima R et al (2003) Mutations in the STK11 gene characterize minimal deviation adenocarcinoma of the uterine cervix. Lab Invest 83(1):35–45CrossRefPubMed
12.
Zurück zum Zitat Chen L, Niu Y, Wan X, Yu L, Zhang X, Strickland AL et al (2021) Clinicopathological features and outcomes in gastric-type of HPV-independent endocervical adenocarcinomas. BMC Cancer 21(1):1095CrossRefPubMedPubMedCentral Chen L, Niu Y, Wan X, Yu L, Zhang X, Strickland AL et al (2021) Clinicopathological features and outcomes in gastric-type of HPV-independent endocervical adenocarcinomas. BMC Cancer 21(1):1095CrossRefPubMedPubMedCentral
13.
Zurück zum Zitat Stoehr A, Nann D, Staebler A, Oberlechner E, Brucker SY, Bachmann C (2019) Difficulties in diagnosis of a minimal deviation adenocarcinoma of uterine cervix diagnosed postoperatively: brief communication and literature review. Arch Gynecol Obstet 300(4):1029–1043CrossRefPubMed Stoehr A, Nann D, Staebler A, Oberlechner E, Brucker SY, Bachmann C (2019) Difficulties in diagnosis of a minimal deviation adenocarcinoma of uterine cervix diagnosed postoperatively: brief communication and literature review. Arch Gynecol Obstet 300(4):1029–1043CrossRefPubMed
14.
15.
Zurück zum Zitat Nakamura A, Yamaguchi K, Minamiguchi S, Murakami R, Abiko K, Hamanishi J et al (2019) Mucinous adenocarcinoma, gastric type of the uterine cervix: clinical features and HER2 amplification. Med Mol Morphol 52(1):52–59CrossRefPubMed Nakamura A, Yamaguchi K, Minamiguchi S, Murakami R, Abiko K, Hamanishi J et al (2019) Mucinous adenocarcinoma, gastric type of the uterine cervix: clinical features and HER2 amplification. Med Mol Morphol 52(1):52–59CrossRefPubMed
16.
Zurück zum Zitat Pirog EC, Lloveras B, Molijn A, Tous S, Guimerà N, Alejo M et al (2014) HPV prevalence and genotypes in different histological subtypes of cervical adenocarcinoma, a worldwide analysis of 760 cases. Mod Pathol 27(12):1559–1567CrossRefPubMed Pirog EC, Lloveras B, Molijn A, Tous S, Guimerà N, Alejo M et al (2014) HPV prevalence and genotypes in different histological subtypes of cervical adenocarcinoma, a worldwide analysis of 760 cases. Mod Pathol 27(12):1559–1567CrossRefPubMed
17.
Zurück zum Zitat Lu S, Shen D, Zhao Y, Kang N, Wang X (2019) Primary endocervical gastric-type adenocarcinoma: a clinicopathologic and immunohistochemical analysis of 23 cases. Diagn Pathol 14(1):72CrossRefPubMedPubMedCentral Lu S, Shen D, Zhao Y, Kang N, Wang X (2019) Primary endocervical gastric-type adenocarcinoma: a clinicopathologic and immunohistochemical analysis of 23 cases. Diagn Pathol 14(1):72CrossRefPubMedPubMedCentral
18.
Zurück zum Zitat Kamath GD, Bhatt A, Ramaswamy V (2017) a rare case of adenoma malignum: preparing for the unforeseen. J Obstet Gynaecol India 67(1):70–73CrossRefPubMed Kamath GD, Bhatt A, Ramaswamy V (2017) a rare case of adenoma malignum: preparing for the unforeseen. J Obstet Gynaecol India 67(1):70–73CrossRefPubMed
19.
Zurück zum Zitat Tsuda H, Mikami Y, Kaku T, Akiyama F, Hasegawa T, Okada S et al (2003) Interobserver variation in the diagnosis of adenoma malignum (minimal deviation adenocarcinoma) of the uterine cervix. Pathol Int 53(7):440–449CrossRefPubMed Tsuda H, Mikami Y, Kaku T, Akiyama F, Hasegawa T, Okada S et al (2003) Interobserver variation in the diagnosis of adenoma malignum (minimal deviation adenocarcinoma) of the uterine cervix. Pathol Int 53(7):440–449CrossRefPubMed
20.
Zurück zum Zitat Lim KT, Lee IH, Kim TJ, Kwon YS, Jeong JG, Shin SJ (2012) Adenoma malignum of the uterine cervix: clinicopathologic analysis of 18 cases. Kaohsiung J Med Sci 28(3):161–164CrossRefPubMed Lim KT, Lee IH, Kim TJ, Kwon YS, Jeong JG, Shin SJ (2012) Adenoma malignum of the uterine cervix: clinicopathologic analysis of 18 cases. Kaohsiung J Med Sci 28(3):161–164CrossRefPubMed
21.
Zurück zum Zitat Talia KL, McCluggage WG (2018) The developing spectrum of gastric-type cervical glandular lesions. Pathology 50(2):122–133CrossRefPubMed Talia KL, McCluggage WG (2018) The developing spectrum of gastric-type cervical glandular lesions. Pathology 50(2):122–133CrossRefPubMed
22.
Zurück zum Zitat Chen YP, Ho SP, Liou WS, Chen CJ (2015) Minimal deviation adenocarcinoma of the uterine cervix. Taiwan J Obstet Gynecol 54(4):447–449CrossRefPubMed Chen YP, Ho SP, Liou WS, Chen CJ (2015) Minimal deviation adenocarcinoma of the uterine cervix. Taiwan J Obstet Gynecol 54(4):447–449CrossRefPubMed
23.
Zurück zum Zitat Karamurzin YS, Kiyokawa T, Parkash V, Jotwani AR, Patel P, Pike MC et al (2015) Gastric-type endocervical adenocarcinoma: an aggressive tumor with unusual metastatic patterns and poor prognosis. Am J Surg Pathol 39(11):1449–1457CrossRefPubMedPubMedCentral Karamurzin YS, Kiyokawa T, Parkash V, Jotwani AR, Patel P, Pike MC et al (2015) Gastric-type endocervical adenocarcinoma: an aggressive tumor with unusual metastatic patterns and poor prognosis. Am J Surg Pathol 39(11):1449–1457CrossRefPubMedPubMedCentral
24.
Zurück zum Zitat Bizzarri N, Pedone Anchora L, Kucukmetin A, Ratnavelu N, Korompelis P, Fedele C et al (2021) Risk of ovarian recurrence after ovarian conservation in early-stage cervical cancer treated with radical surgery: a propensity match analysis. Eur J Surg Oncol 47(8):2158–2165CrossRefPubMed Bizzarri N, Pedone Anchora L, Kucukmetin A, Ratnavelu N, Korompelis P, Fedele C et al (2021) Risk of ovarian recurrence after ovarian conservation in early-stage cervical cancer treated with radical surgery: a propensity match analysis. Eur J Surg Oncol 47(8):2158–2165CrossRefPubMed
25.
Zurück zum Zitat Theplib A, Hanprasertpong J, Leetanaporn K (2020) Safety and prognostic impacts of ovarian preservation during radical hysterectomy for early-stage adenocarcinoma and adenosquamous cervical cancer. Biomed Res Int 2020:5791381CrossRefPubMedPubMedCentral Theplib A, Hanprasertpong J, Leetanaporn K (2020) Safety and prognostic impacts of ovarian preservation during radical hysterectomy for early-stage adenocarcinoma and adenosquamous cervical cancer. Biomed Res Int 2020:5791381CrossRefPubMedPubMedCentral
26.
Zurück zum Zitat Touhami O, Plante M (2015) Should ovaries be removed or not in (early-stage) adenocarcinoma of the uterine cervix: a review. Gynecol Oncol 136(2):384–388CrossRefPubMed Touhami O, Plante M (2015) Should ovaries be removed or not in (early-stage) adenocarcinoma of the uterine cervix: a review. Gynecol Oncol 136(2):384–388CrossRefPubMed
Metadaten
Titel
Novel predictors for identifying cervical minimal deviation adenocarcinoma patients with poor prognosis: a long-term observational study in a tertiary centre
verfasst von
Yiting Bao
Hao Zhang
Wu Huang
Xukai Luo
Liangqing Yao
Guannan Feng
Lei Yuan
Publikationsdatum
11.09.2023
Verlag
Springer Berlin Heidelberg
Erschienen in
Archives of Gynecology and Obstetrics / Ausgabe 4/2024
Print ISSN: 0932-0067
Elektronische ISSN: 1432-0711
DOI
https://doi.org/10.1007/s00404-023-07207-1

Weitere Artikel der Ausgabe 4/2024

Archives of Gynecology and Obstetrics 4/2024 Zur Ausgabe

Images in Obstetrics and Gynecology

Youssef syndrome

Alter der Mutter beeinflusst Risiko für kongenitale Anomalie

28.05.2024 Kinder- und Jugendgynäkologie Nachrichten

Welchen Einfluss das Alter ihrer Mutter auf das Risiko hat, dass Kinder mit nicht chromosomal bedingter Malformation zur Welt kommen, hat eine ungarische Studie untersucht. Sie zeigt: Nicht nur fortgeschrittenes Alter ist riskant.

Fehlerkultur in der Medizin – Offenheit zählt!

28.05.2024 Fehlerkultur Podcast

Darüber reden und aus Fehlern lernen, sollte das Motto in der Medizin lauten. Und zwar nicht nur im Sinne der Patientensicherheit. Eine negative Fehlerkultur kann auch die Behandelnden ernsthaft krank machen, warnt Prof. Dr. Reinhard Strametz. Ein Plädoyer und ein Leitfaden für den offenen Umgang mit kritischen Ereignissen in Medizin und Pflege.

Mammakarzinom: Brustdichte beeinflusst rezidivfreies Überleben

26.05.2024 Mammakarzinom Nachrichten

Frauen, die zum Zeitpunkt der Brustkrebsdiagnose eine hohe mammografische Brustdichte aufweisen, haben ein erhöhtes Risiko für ein baldiges Rezidiv, legen neue Daten nahe.

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

24.05.2024 Mammakarzinom Nachrichten

In der MONARCHE-3-Studie lebten Frauen mit fortgeschrittenem Hormonrezeptor-positivem, HER2-negativem Brustkrebs länger, wenn sie zusätzlich zu einem nicht steroidalen Aromatasehemmer mit Abemaciclib behandelt wurden; allerdings verfehlte der numerische Zugewinn die statistische Signifikanz.

Update Gynäkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.